Issue

Vol. 32 No. 2 (2020): Vol 32 Issue 2

Copyright (c) 2020 AJC

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Anti-HIV, Antitubercular and Antibacterial Activities of Novel 3-(Substituted Quinazolinylamino)-2-phenyl quinazolin-4(3H)ones

https://doi.org/10.14233/ajchem.2020.22280
M.T. Sulthana
Medicinal Chemistry Research Laboratory, MNR College of Pharmacy, Sangareddy-502294, India
K. Chitra
Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research (Deemed to be University), Porur, Chennai-600116, India
V. Alagarsamy
Medicinal Chemistry Research Laboratory, MNR College of Pharmacy, Sangareddy-502294, India

Corresponding Author(s) : V. Alagarsamy

drvalagarsamy@gmail.com

Asian Journal of Chemistry, Vol. 32 No. 2 (2020): Vol 32 Issue 2

Abstract

In the present study, we have synthesized a series of novel 2-phenyl-3-(substituted quinazolinylamino)quinazolin-4(3H)-ones by the reaction of 3-(substituted)-2-hydrazinoquinazoline-4(3H)-ones with 2-phenyl-3,1-benzoxazin-4-one. The starting material 3-(substituted)-2-hydrazinoquinazolin-4(3H)-ones were synthesized from various primary amines. All the synthesized compounds were screened for their antitubercular, anti-HIV and antibacterial activity against different Gram-positive and Gram-negative strains by agar dilution method. Among the test compounds, 3-(4-nitrophenyl)-2-(4-oxo-2-phenylquinazolin-3(4H)-ylamino)quinazolin-4(3H)-one (BQZ6) and 3-(4-chlorophenyl)-2-(4-oxo-2-phenylquinazolin-3(4H)-ylamino)quinazolin-4(3H)-one (BQZ7) shown most potent antibacterial activity against E. coli, P. aeruginosa and S. aureus with the MIC of 3 μg/mL. The compound BQZ7 exhibited the antitubercular activity with the MIC of 25 μg/mL and anti-HIV activity with the MIC of 35.4 μg/mL against HIV1 and HIV2 and offers potential lead for further optimization and development to new antitubercular and anti-HIV agents. The results from this study confirm that the synthesized and biologically evaluated quinazolines showed promising antimicrobial, antitubercular and anti-HIV activities and are new scaffolds for antimicrobial activity.

Keywords

Quinazolines Antibacterial activity Antitubercular activity Anti-HIV activity
Sulthana, M., Chitra, K., & Alagarsamy, V. (2019). Anti-HIV, Antitubercular and Antibacterial Activities of Novel 3-(Substituted Quinazolinylamino)-2-phenyl quinazolin-4(3H)ones. Asian Journal of Chemistry, 32(2), 281–286. https://doi.org/10.14233/ajchem.2020.22280
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. World Health Organization, Global Tuberculosis Report 2018, World Health Organization: Geneva, Switzerland (2018).
  2. T.T. Balcha, S. Skogmar, E. Sturegard, P. Björkman and N. Winqvist, Glob. Health Action, 8, 27048 (2015); https://doi.org/10.3402/gha.v8.27048.
  3. M.J. Reid and N.S. Shah, Lancet Infect. Dis., 9, 173 (2009); https://doi.org/10.1016/S1473-3099(09)70043-X.
  4. World Health Organization Tuberculosis, Available online: https://www.who.int/tb/en/ (accessed on 17 March 2019).
  5. V. Alagarsamy, K. Chitra, G. Saravanan, V.R. Solomon, M.T. Sulthana and B. Narendhar, Eur. J. Med. Chem., 151, 628 (2018); https://doi.org/10.1016/j.ejmech.2018.03.076.
  6. A. Hameed, M. Al-Rashida, M. Uroos, S.A. Ali, Arshia, M. Ishtiaq and K.M. Khan, Expert Opin. Ther. Pat., 28, 281 (2018); https://doi.org/10.1080/13543776.2018.1432596.
  7. F.R. Pavan, P.I.S. Maia, S.R.A. Leite, V.M. Deflon, A.A. Batista, D.N. Sato, S.G. Franzblau and C.Q.F. Leite, Eur. J. Med. Chem., 45, 1898 (2010); https://doi.org/10.1016/j.ejmech.2010.01.028.
  8. O. Güzel, N. Karali and A. Salman, Bioorg. Med. Chem., 16, 8976 (2008); https://doi.org/10.1016/j.bmc.2008.08.050.
  9. N. Karali, A. Gürsoy, F. Kandemirli, N. Shvets, F.B. Kaynak, S. Ozbey, V. Kovalishyn and A. Dimoglo, Bioorg. Med. Chem., 15, 5888 (2007); https://doi.org/10.1016/j.bmc.2007.05.063.
  10. D. Sriram, P. Yogeeswari, R. Thirumurugan and R.K. Pavana, J. Med. Chem., 49, 3448 (2006); https://doi.org/10.1021/jm060339h.
  11. D. Sriram, P. Yogeeswari, P. Dhakla, P. Senthilkumar, D. Banerjee and T.H. Manjashetty, Bioorg. Med. Chem. Lett., 19, 1152 (2009); https://doi.org/10.1016/j.bmcl.2008.12.088.
  12. E. Saripinar, Y. Güzel, S. Patat, I. Yildirim, Y. Akçamur and A.S. Dimoglo, Arzneimittelforschung, 46, 824 (1996).
  13. B. Milczarska, H. Foks, J. Sokolowska, M. Janowiec, Z. Zwolska and Z. Andrzejczyk, Acta Pol. Pharm., 56, 121 (1999).
  14. G. Turan-Zitouni, A. Özdemir, Z. Asim Kaplancikli, K. Benkli, P. Chevallet and G. Akalin, Eur. J. Med. Chem., 43, 981 (2008); https://doi.org/10.1016/j.ejmech.2007.07.001.
  15. S.A. Shiba, A.A. El-Khamry, M.E. Shaban and K.S. Atia, Pharmazie, 52, 189 (1997).
  16. D. Sriram, P. Yogeeswari, J.S. Basha, D.R. Radha and V. Nagaraja, Bioorg. Med. Chem., 13, 5774 (2005); https://doi.org/10.1016/j.bmc.2005.05.063.
  17. P. Shanmugavelan, S. Nagarajan, M. Sathishkumar, A. Ponnuswamy, P. Yogeeswari and D. Sriram, Bioorg. Med. Chem. Lett., 21, 7273 (2011); https://doi.org/10.1016/j.bmcl.2011.10.048.
  18. J. Kunes, J. Bazant, M. Pour, K. Waisser, M. Slosárek and J. Janota, Il Farmaco, 55, 725 (2000); https://doi.org/10.1016/S0014-827X(00)00100-2.
  19. R. Pauwels, E. De Clercq, J. Desmyter, J. Balzarini, P. Goubau, P. Herdewijn, H. Vanderhaeghe and M. Vandeputte, J. Virol. Methods, 16, 171 (1987); https://doi.org/10.1016/0166-0934(87)90002-4.
  20. A. Barry, Antibiotics in Laboratory Medicine, William and Wilkins: Baltimore, MD, edn 5, vol. 1 (1991).
  21. S.N. Pandeya, D. Sriram, G. Nath and E. De Clercq, Il Farmaco, 54, 624 (1999); https://doi.org/10.1016/S0014-827X(99)00075-0.
Read More
Author biographies is not available.
Download
PDF
Statistic
Read Counter : 0 Download : 0